| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to the
consolidated net loss for the years ended December 31, 2024, and 2023 is included at the bottom of the table below.
| |
|
As of December 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Significant segment expenses |
|
|
|
|
|
|
| General and administrative (1) |
|
$ |
5,786,293 |
|
|
$ |
6,306,707 |
|
| Pre-clinical research (1) |
|
|
1,479,896 |
|
|
|
3,584,483 |
|
| CMC (1) |
|
|
1,463,530 |
|
|
|
2,490,729 |
|
| Clinical development (1) |
|
|
4,097,521 |
|
|
|
1,652,808 |
|
| License milestone payments |
|
|
- |
|
|
|
250,000 |
|
| Depreciation and amortization |
|
|
649,029 |
|
|
|
648,454 |
|
| Share based compensation expense |
|
|
773,693 |
|
|
|
592,269 |
|
| Other segment items (2) |
|
|
- |
|
|
|
453,911 |
|
| Total operating and segment expenses |
|
$ |
14,249,962 |
|
|
$ |
15,979,361 |
|
| |
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
77,806 |
|
|
|
(56,245 |
) |
| Interest and dividends, net |
|
|
(423,184 |
) |
|
|
(415,368 |
) |
| Adjustments and reconciling items (3) |
|
|
- |
|
|
|
453,910 |
|
| Segment and consolidated net loss |
|
$ |
13,904,584 |
|
|
$ |
15,961,658 |
|
|
(1) |
includes personnel costs and excludes share-based compensation
expense |
|
(2) |
includes litigation settlements, loss from sale of assets, and
loss on asset write offs |
|
(3) |
includes net loss from discontinued operations |
|